Epidermolysis bullosa acquisita: Autoimmunity to anchoring fibril collagen

References

• Elliott GT. Two cases of epidermolysis bullosa. J Cutan Genitourin Dis. 1895; 13:10.
   Google Scholar
• Roenigk HH, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita: Report of three cases and review of all published cases. Arch Dermatol. 1971; 103:1–10.
   PubMed Web of Science ®Google Scholar
• Yaoita H, Briggaman A, Lawley TJ. Epidermolysis bullosa acquisita: Ultrastructural and immunological studies. J Invest Dermatol. 1981; 76:288–292.
   PubMed Web of Science ®Google Scholar
• Nieboer C, Boorsma DM, Woerdeman MJ. Epidermolysis bullosa acquisita: Immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients. Br J Dermatol. 1980; 102:383–392.
   PubMed Web of Science ®Google Scholar
• Gammon WR, Briggaman RA, Woodley DT, Heald PW, Wheeler CEJr. Epidermolysis bullosa acquisita—a pemphigoid like disease. J Am Acad Dermatol. 1984; 11:820–832.
   PubMed Web of Science ®Google Scholar
• Woodley DT. Epidermolysis bullosa acquisita. Prog Dermatol. 1988; 22:1.
   Google Scholar
• Dahl MG. Epidermolysis bullosa acquisita—a sign of cicatricial pemphigoid?. Br J Dermatol. 1979; 101:475–483.
   PubMed Web of Science ®Google Scholar
• Kurzhals G, Stolz W, Meurer M, Kunze J, Braun-Falco O, Krieg T. Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid. Arch Dermatol. 1991; 127:391–395.
   PubMedGoogle Scholar
• Richter BJ, McNutt NS. The spectrum of epidermolysis bullosa acquisita. Arch Dermatol. 1979; 115:1325–1328.
   PubMedGoogle Scholar
• Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement membrane autoantigen in epidermolysis bullosa aquisita. N Engl J Med. 1984; 310:1007–1015.
   PubMed Web of Science ®Google Scholar
• Woodley DT, Burgeson RE, Lunstrum G, Bruckner-Tuderman L, Reese MJ, Briggaman RA. The epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest. 1988; 81:683–687.
   PubMed Web of Science ®Google Scholar
• Gammon WR, Woodley DT, Dole KC, Briggaman RA. Evidence that basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigens. J Invest Dermatol. 1985; 84:472–476.
   PubMed Web of Science ®Google Scholar
• Gammon WR, Heise ER, Burke WA, Fine JD, Woodley DT, Briggaman RA. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: Evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol. 1988; 91:228–232.
   PubMed Web of Science ®Google Scholar
• Gammon WR, Briggaman RA. Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus: Disease of autoimmunity to type VII collagen. Dermatol Clin. 1993; 11:535–547.
   PubMed Web of Science ®Google Scholar
• Lee CW. Prevalences of subacute cutaneous lupus erythematosus and epidermolysis bullosa acquisita among Korean/oriental papulations. Dermatology. 1998; 197:187.
   PubMed Web of Science ®Google Scholar
• Arpey CJ, Elewski BE, Moritz DK, Gammon WR. Childhood epidermolysis bullosa acquisita: Report of three cases and review of literature. J Am Acad Dermatol. 1991; 24:706–714.
   PubMed Web of Science ®Google Scholar
• Gammon WR. Epidermolysis bullosa acquisita. Semin Dermatol. 1988; 7:218–224.
   PubMedGoogle Scholar
• Keene DR, Sakai LY, Lunstrum GP, Morris NP, Burgeson RE. Type VII collagen forms an extended network of anchoring fibrils. J Cell Biol. 1987; 104:611–621.
   PubMed Web of Science ®Google Scholar
• Chen M, Marinkovich MP, Veis A, Cai X, Rao CN, O'Toole EA, Woodley DT. Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal–dermal adherence in human skin. J Biol Chem. 1997; 272:14516–14522.
   PubMed Web of Science ®Google Scholar
• Lapiere JC, Woodley DT, Parente MG. Epitope mapping of type VII collagen: Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest. 1993; 92:1831–1839.
   PubMed Web of Science ®Google Scholar
• Jones DA, Hunt SWIII, Prisayanh PS, Briggaman RA, Gammon WR. Immunodominant autoepitopes of type VII collagen are short, paired peptide sequences within the fibronectin type III homology region of the noncollagenous (NC1) domain. J Invest Dermatol. 1995; 104:231–235.
   PubMed Web of Science ®Google Scholar
• Woodley DT, O'Keefe EJ, McDonald JA, Reese MJ, Briggaman RA, Gammon WR. Specific affinity between fibronectin and the epidermolysis bullosa acquisita antigen. J Clin Invest. 1987; 179:1826–1830.
   Google Scholar
• Park SB, Cho KH, Youn JL, Hwang DH, Kim SC, Chung JH. Epidermolysis bullosa acquisita in childhood—a case mimicking chronic bullous dermatosis of childhood. Clin Exp Dermatol. 1997; 22:220–222.
   PubMed Web of Science ®Google Scholar
• Callot-Mellot C, Bodemer C, Caux F, Bourgault-Villada I, Fraitag S, Goudié G, Heller M, de Prost Y, Prost C. Epidermolysis bullosa aquisita in childhood. Arch Dermatol. 1997; 133:1122–1126.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Ishida-Yamamoto A, Hashimoto T, Hiramoto K, Harada T, Kawachi Y, Shimizu H, Tanaka T, Kishiyama K, Höpfner B, Takahashi H, Iizuka H, Bruckner-Tuderman L. A novel variant of acquired epidermolysis bullosa with autoantibodies against the central triple-helical domain of type VII collagen. Lab Invest. 1997; 77:623–632.
   PubMed Web of Science ®Google Scholar
• Lapiere JC, Chen JD, Iwasaki T, Hu L, Uitto J, Woodley DT. Type VII collagen specifically binds fibronectin via a unique subdomain within the collagenous triple helix. J Invest Dermatol. 1994; 103:637–641.
   PubMed Web of Science ®Google Scholar
• Chen M, Keene DR, Costa FK, Tahk SH, Woodley DT. The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis bullosa acquisita autoantibodies. J Biol Chem. 2001; 276:21649–21655.
   PubMed Web of Science ®Google Scholar
• Sitaru C, Kromminga A, Hashimoto T, Bröcker EB, Zillikens D. Autoantibodies to type VII collagen mediate Fcgamma-dependen granulocyte activation and induce dermal–epidermal separation in cryosections of human skin. Am J Pathol. 2002; 161:301–311.
   PubMed Web of Science ®Google Scholar
• Woodley DT, Chang C, Saadat P, Ram R, Liu Z, Chen M. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol. 2005; 124:958–964.
   PubMed Web of Science ®Google Scholar
• Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D. Induction of dermal–epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest. 2005; 115:870–878.
   PubMed Web of Science ®Google Scholar
• Woodley DT, Ram R, Doostan A, Bandyopadhyay P, Huang Y, Remington J, Hou Y, Keene DR, Liu Z, Chen M. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol. 2006; 126:1323–1330.
   PubMed Web of Science ®Google Scholar
• Woodley DT, Doostan A, Bandyopadhyay P, Remington J, Wang X, Hou Y, Liu Z, Woodley DT. The cartilage matrix protein subdomain of type VII collagen is a newly recognized antigenic and pathogenic epitope for epidermolysis bullosa acquisita. Am J Pathol. 2007; 170:2009–2018.
   PubMed Web of Science ®Google Scholar
• Sitaru C, Chiriac MT, Mihai S, Büning J, Gebert A, Ishiko A, Zillikens D. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol. 2006; 177:3461–3468.
   PubMed Web of Science ®Google Scholar
• Sitaru C. Experiment models of epidermolysis bullosa acquisita. Exp Dermatol. 2007; 16:520–531.
   PubMed Web of Science ®Google Scholar
• Harman KE, Whittam LR, Wakelin SH, Black MM. Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin. Br J Dermatol. 1998; 139:1126–1127.
   PubMed Web of Science ®Google Scholar
• Stewart MI, Woodley DT, Briggaman RA. Acquired epidermolysis bullosa and associated symptomatic esophageal webs. Arch Dermatol. 1991; 127:373–377.
   PubMedGoogle Scholar
• Gammon WR, Briggaman RA, Wheeler CEJr. Epidermolysis bullosa acquisita presenting as an inflammatory bullous disease. J Am Acad Dermatol. 1982; 7:382–387.
   PubMed Web of Science ®Google Scholar
• Wieme N, Lambert J, Moerman M, Geerts ML, Temmerman L, Naeyaert JM. Epidermolysis bullosa acquisita with combined features of bullous pemphigoid and cicatricial pemphigoid. Dermatology. 1999; 198:310–313.
   PubMed Web of Science ®Google Scholar
• Tokuda Y, Amagai M, Yaoita H, Kawachi S, Ito T, Matsuyama I, Tsuchiya S, Saida T. A case of inflammatory variant of epidermolysis bullosa acquisita: Chronic bullous dermatosis associated with non scarring mucosal blisters and circulating IgG anti-type-VII-collagen antibody. Dermatology. 1998; 197:58–61.
   PubMed Web of Science ®Google Scholar
• Yancey KB. 1998. Cicatricial pemphigoid. In: Fitzpatrick TB, Eisen AZ. editors. Dermatology in general medicine. New York: McGraw-Hill674–679.
   Google Scholar
• Hashimoto T, Ishiko A, Shimizu H, Tanaka T, Dodd HJ, Bhogal BS, Black MM, Nishikawa T. A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies. Br J Dermatol. 1996; 134:336–339.
   PubMed Web of Science ®Google Scholar
• Rusenko KW, Gammon WR, Briggaman RA. Type VII collagen is the antigen recognized by IgA anti-sub lamina densa autoantibodies. J Invest Dermatol. 1989; 92:510 Abstract.
   Web of Science ®Google Scholar
• Bauer JW, Schaeppi H, Metze D, Muss W, Pohla-Gubo G, Hametner R, Ruckhofer J, Grabner G, Hintner H. Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol. 1999; 141:887–892.
   PubMed Web of Science ®Google Scholar
• Lee CW. Serum IgA autoantibodies in patients with epidermolysis bullosa acquisita: A high frequency of detection. Dermatology. 2000; 200:83–84.
   PubMed Web of Science ®Google Scholar
• Edwards S, Wakelin SH, Wojnarowska F, Marsden RA, Kirtschig G, Bhogal B, Black MM. Bullous pemphigoid and epidermolysis bullosa acquisita: Presentation, prognosis, and immunopathology in 11 children. Pediatr Dermatol. 1998; 15:184–190.
   PubMed Web of Science ®Google Scholar
• Lever WF, Schaumburg-Lever G. 1990. Congenital disease (genodermatoses). In: Lever WF, Schaumburg-Lever G. editors. Histopathology of the skin. Philadephia: Lippincott78.
   Google Scholar
• Ackerman ABHistologic disease of inflammatory skin diseases. In: Bennis B, Reichel M, Rondall MB. editors. An algorithmic method based on pattern analysis. Baltimore: Williams & Wilkins379–4401978.
   Google Scholar
• Ray TL, Levine JB, Weiss W, Ward PA. Epidermolysis bullosa acquisita and inflammatory bowel disease. J Am Acad Dermatol. 1982; 6:242–252.
   PubMed Web of Science ®Google Scholar
• Fine JD, Tyring S, Gammon WR. The presence of intra-lamina lucida blister formation in epidermolysis bullosa acquisita: Possible role of leukocytes. J Invest Dermatol. 1989; 92:27–32.
   PubMed Web of Science ®Google Scholar
• Briggaman RA, Wheeler CEJr. The epidermal–dermal junction. J Invest Dermatol. 1975; 65:71–84.
   PubMed Web of Science ®Google Scholar
• Briggaman RA, Schechter NM, Fraki J. Degradation of the epidermal–dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes. J Exp Med. 1980; 160:1027–1042.
   Google Scholar
• Klein GF, Hintner H, Schuler G, Fritsch P. Junctional blisters in acquired bullous disorders of the dermal–epidermal junction zone: Role of the lamina lucida as the mechanical locus minoris resistentiae. Br J Dermatol. 1983; 109:499–508.
   PubMed Web of Science ®Google Scholar
• Kushniruk W. The immunopathology of epidermolysis bullosa acquisita. Can Med Assoc J. 1973; 108:1143–1146.
   PubMed Web of Science ®Google Scholar
• Epstein JH, Tuffanelli DL, Epstein WL. Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol. 1973; 107:689–698.
   PubMedGoogle Scholar
• Paller AS, Queen LL, Woodley DT, Lane AT, Gammon WR, Briggaman RA. Organ-specific, phylogenetic, and ontogenetic distribution of the epidermolysis bullosa acquisita antigen. J Invest Dermatol. 1986; 86:376–379.
   PubMed Web of Science ®Google Scholar
• Woodley DT, Sauder D, Talley MJ, Silver M, Grotendorst G, Qwarnstrom E. Localization of basement membrane components after dermal–epidermal junction separation. J Invest Dermatol. 1983; 81:149.
   PubMed Web of Science ®Google Scholar
• Gammon WR, Briggaman RA, Inman AO. Differentiating anti-lamina lucida and antisublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol. 1984; 82:139–144.
   PubMed Web of Science ®Google Scholar
• Ghohestani RF, Nicolas JF, Roussele P. Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol. 1997; 133:1102–1107.
   PubMedGoogle Scholar
• Mayuzumi M, Akiyama M, Nishie W, Ukae S, Abe M, Sawamura D, Hashimoto T, Shimizu H. Childhood epidermolysis bullosa acquisita with autoantibodies against the noncollagenous 1 and 2 domains of type VII collagen: Case report and review of the literature. Br J Dermatol. 2006; 155:1048–1052.
   PubMed Web of Science ®Google Scholar
• Domloge-Hultsch N, Anhalt GJ, Gammon WR, Lazarova Z, Briggaman R, Welch M, Jabs DA, Huff C, Yancey KB. Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch Dermatol. 1994; 130:1521–1529.
   PubMedGoogle Scholar
• Chan LS, Fine JD, Briggaman RA, Woodley DT, Hammerberg C, Drugge RJ, Cooper KD. Identification and partial characterization of a novel 105-kDalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease. J Invest Dermatol. 1993; 101:262–267.
   PubMed Web of Science ®Google Scholar
• Zillikens D, Ishiko A, Jonkman MF, Chimanovitch I, Shimizu H, Hashimoto T, Bröcker EB. Autoantibodies in anti-p200 pemphigoid stain skin lacking laminin 5 and type VII collagen. Br J Dermatol. 2000; 143:1043–1049.
   PubMed Web of Science ®Google Scholar
• Vodegel RM, Kiss M, De Jong MCJM, Pas HH, Altmayer A, Molnar K, Husz S, Van Der Meer JB, Jonkman MF. The use of skin substrates deficient in basement membrane molecules for the diagnosis of subepidermal autoimmune bullous disease. Eur J Dermatol. 1998; 8:83–85.
   PubMed Web of Science ®Google Scholar
• Jonkman MF, Schuur J, Dijk F, Heeres K, de Jong MC, van der Meer JB, Yancey KB, Pas HH. Inflammatory variant of epidermolysis bullosa acquisita with IgG autoantibodies against type VII collagen and laminin α3. Arch Dermatol. 2000; 136:227–231.
   PubMedGoogle Scholar
• Feliciani C, Di Muzio M, Mohammad Pour S, Allegretti T, Amerio P, Toto P, Coscione G, Proietto G, Amerio P. “Suction split” as a routine method to differentiate epidermolysis bullosa acquisita from bullous pemphigoid. J Eur Acad Dermatol Venereol. 1998; 10:243–247.
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan T, Robin H, Heller M, Caux F, Prost C. Epidermolysis bullosa acquisita diagnosed by direct immunoelectron microscopy of the conjunctiva. Ophthalmology. 1997; 104:1414–1420.
   PubMed Web of Science ®Google Scholar
• Prost C, Dubertret L, Fosse M, Wechsler J, Touraine R. A routine immuno-electron microscopic technique for localizing an auto-antibody on epidermal basement membrane. Br J Dermatol. 1984; 110:1–7.
   PubMed Web of Science ®Google Scholar
• Chen M, Costa FK, Lindvay CR, Han YP, Woodley DT. The recombinant expression of full-length type VII collagen and characterization of molecular mechanisms underlying dystrophic epidermolysis bullosa. J Biol Chem. 2002; 277:2118–2124.
   PubMed Web of Science ®Google Scholar
• Chen M, Chan LS, Cai X, O'Toole EA, Sample JC, Woodley DT. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol. 1997; 108:68–72.
   PubMed Web of Science ®Google Scholar
• De Jong MC, Bruins S, Heeres K, Jonkman MF, Nieboer C, Boorsma DM, Pas HH, van der Meer JB. Bullous pemphigoid and epidermolysis bullosa acquisita: Differentiation by fluorescence overlay antigen mapping. Arch Dermatol. 1996; 132:151–157.
   PubMedGoogle Scholar
• Kazama T, Yamamoto Y, Hashimoto T, Komai A, Ito M. Application of confocal laser scanning microscopy to differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. Br J Dermatol. 1998; 138:593–601.
   PubMed Web of Science ®Google Scholar
• Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T, Kirtschig G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich MP, Mondino BJ, Prost-Squarcioni C, Rogers RS3rd, Setterfield JF, West DP, Wojnarowska F, Woodley DT, Yancey KB, Zillikens D, Zone JJ. The first international consensus on mucous membrane pemphigoid: Definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002; 138:370–379.
   PubMed Web of Science ®Google Scholar
• Hundorfean G, Neurath MF, Sitaru C. Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med. 2010; 10:2393–2403.
   Google Scholar
• Chan LS, Woodley DT. 1996. Pemphigoid: Bullous and cicatricial. In: Lichtenstein LM, Fauci AS. editors. Current therapy in allergy, immunology and rhematologyMosby St Louis5–93.
   Google Scholar
• Chen M, O'Toole EA, Sanghavi J, Mahmud N. Kelleher D Type VII collagen exists in human intestine and serves as an antigenic target in patients with inflammatory bowel disease. J Invest Dermatol. 1997; 108:542.
   Web of Science ®Google Scholar
• Oostingh GJ, Sitaru C, Zillikens D, Kromminga A, Lührs H, Kromminga A, Lührs H. Subclass distribution of type VII collagen-specific autoantibodies in patients with inflammatory bowel disease. J Dermatol Sci. 2005; 37:182–184.
   PubMed Web of Science ®Google Scholar
• Lohi J, Leivo I, Tani T, Kiviluoto T, Kivilaakso E, Burgeson RE, Virtanen I. Laminins, tenascin and type VII collagen in colorrectal mucosa. Histochem J. 1996; 28:431–440.
   PubMedGoogle Scholar
• Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB. Epitope spreading: Lessons from autoimmune skin diseases. J Invest Dermatol. 1998; 110:103–109.
   PubMed Web of Science ®Google Scholar
• Mekori YA, Chowers Y, Ducker I, Klajman A. Inhibition of delayed hypersensitivity reaction by colchicine: Colchicine inhibits interferon-gamma-induced expression of HLA-DR on a epithelial cell line. Clin Exp Immunol. 1989; 78:230–232.
   PubMed Web of Science ®Google Scholar
• Megahed M, Scharfetter-Kochnek K. Epidermolysis bullosa acquisita-successful treatment with colchicine. Arch Dermatol Res. 1984; 286:35–46.
   Google Scholar
• Cunningham BB, Kirchmann TT, Woodley DT. Colchicine for epidermolysis bullosa (EBA). J Am Acad Dermatol. 1996; 34:781–784.
   PubMed Web of Science ®Google Scholar
• Ishii N, Hamada T, Dainichi T, Karashima T, Nakama T, Yasumoto S, Zillikens D, Hashimoto T. Epidermolysis bullosa acquisita: What's new?. J Dermatol. 2010; 37:220–230.
   PubMed Web of Science ®Google Scholar
• Saha M, Cutler T, Bhogal B, Black MM, Groves RW. Refractory epidermolysis bullosa acquisita: Successful treatment with rituximab. Clin Exp Dermatol. 2009; 34:979–980.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Benoit S, Brocker EB, Zillikens D, Goebeler M. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol. 2006; 142:147–150.
   PubMedGoogle Scholar
• Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007; 156:194–196.
   PubMed Web of Science ®Google Scholar
• Neidermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007; 143:192–198.
   PubMedGoogle Scholar
• Sadler E, Schafleitner B, Lanschuetzer C, Laimer M, Pohla-Gubo G, Hametner R, Hintner H, Bauer JW. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol. 2007; 157:417–419.
   PubMed Web of Science ®Google Scholar
• Hallel-Halevy D, Nadelman C, Chen M, Woodley DT. Epidermolysis bullosa acquisita: Update and review. Clin Dermatol. 2001; 19:712–718.
   PubMed Web of Science ®Google Scholar
• Engineer L, Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol. 2001; 44:818–828.
   PubMed Web of Science ®Google Scholar
• Mutasim DF. Management of autoimmune bullous diseases: Pharmacology and therapeutics. J Am Acad Dermatol. 2004; 51:859–877.
   PubMed Web of Science ®Google Scholar
• Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: A systematic literature review. Arch Dermatol. 2002; 138:380–384.
   PubMed Web of Science ®Google Scholar
• Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hintner H, Romani N, Fritsch P. Intravenous immunoglobulin treatment in therapy—resistant epidermolysis bullosa acquisita. J Am Acad Dermatol. 1997; 36:331–335.
   PubMed Web of Science ®Google Scholar
• Caldwell JB, Yancey KB, Engler RJ, James WD. Epidermolysis bullosa acquisita: Efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol. 1994; 31:827–828.
   PubMed Web of Science ®Google Scholar
• Mohr C, Sunderkotter C, Hildebrand A, Biel K, Rütter A, Rütter GH, Luger TA, Kolde G. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol. 1995; 132:824–826.
   PubMed Web of Science ®Google Scholar
• Harman KE, Black MM. High-dose intravenous immunoglobulin for the treatment of autoimmune blistering diseases: An evaluation of its use in 14 cases. Br J Dermatol. 1999; 140:864–874.
   Web of Science ®Google Scholar
• Gourgiotou K, Exadaktylou D, Aroni K, Rallis E, Nicolaidou E, Paraskevakou H, Katsambas AD. Epidermolysis bullosa acquisita: Treatment with intravenous immunoglobulins. J Eur Acad Dermatol Venereol. 2002; 16:77–80.
   PubMed Web of Science ®Google Scholar
• Campos M, Silvente C, Lecona M, Suárez R, Lázaro P. Epidermolysis bullosa acquisita: Diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin. Clin Exp Dermatol. 2006; 31:71–73.
   PubMed Web of Science ®Google Scholar
• Segura S, Iranzo P, Martínez DE, Mascaró JMJr, Alsina M, Herrero J, Herrero C. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: Evaluation of its use in 19 cases. J Am Acad Dermatol. 2007; 56:960–967.
   PubMed Web of Science ®Google Scholar
• Miller JK, Stricklin GP, Fine JD, King LE, Arzubiaga MC, Ellis DL. Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy. Br J Dermatol. 1995; 133:467–471.
   PubMed Web of Science ®Google Scholar
• Rook AH, Jegasothy BV, Heald P, Nahass GT, Ditre C, Witmer WK, Lazarus GS, Edelson RL. Extracoporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med. 1990; 112:303–305.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol. 1997; 136:415–420.
   PubMed Web of Science ®Google Scholar
• Crow LL, Finkle JP, Gammon WR, Woodley DT. Cleaning of epidermolysis bullosa acquisita on cyclosporine. J Am Acad Dermatol. 1988; 19:937–942.
   PubMed Web of Science ®Google Scholar
• Connolly SM, Sander HM. Treatment of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol. 1987; 16:890.
   PubMed Web of Science ®Google Scholar
• Gammon WR, Murrell DF, Jenison MW, Padilla KM, Prisyanh PS, Jones DA, Briggaman RA, Hunt SW Jr. Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J Invest Dermatol. 1993; 100:618–622.
   PubMed Web of Science ®Google Scholar
• Gammon WR, Inman AO 3rd, Wheeler CE Jr.. Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods. J Invest Dermatol. 1984; 83:57–61.
   PubMed Web of Science ®Google Scholar